Zentalis Pharmaceuticals Inc

Nyitva

4.46 2.53

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.43

Maximum

4.55

Fő mutatók

By Trading Economics

Bevétel

-136K

-35M

Egy részvényre jutó nyereség

-0.503

Munkavállalók

106

EBITDA

2.2M

-35M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+56.95% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

33M

328M

Előző nyitás

1.93

Előző zárás

4.46

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 2. 23:56 UTC

Macro News

FTSE 100 Index rises in after-market hours as inflation concerns ease. Positive corporate news and U.S. employment data support the upward momentum.

2026. júl. 2. 23:56 UTC

Correlated Moves

EUR/TRY is higher in Thursday's session, supported by a modest increase since Wednesday's close. The pair remains volatile within its one-month range.

2026. júl. 2. 23:56 UTC

ETF Constituents

The Vanguard FTSE Emerging Markets ETF was little changed in after-market hours, with INFY, TCOM, and JD contributing slight declines.

2026. júl. 2. 23:51 UTC

Asia equity markets decline amid semiconductor sell-off, while U.S. indices rise on weak job data easing rate hike fears; European markets gain as defensive sectors lead.

2026. júl. 2. 23:51 UTC

U.S. job growth disappoints with only 57k added in June, prompting reassessment of Fed rate hike expectations, while global markets show mixed signals amid easing inflation concerns.

2026. júl. 2. 23:51 UTC

US equity indices rise as lower-than-expected job growth eases interest rate hike fears, while European markets gain and Asian stocks face losses.

2026. júl. 2. 23:51 UTC

European equity markets rise on positive economic data and easing inflation, with Germany's DAX up 1.9% and Italy's unemployment hitting a record low of 5.0%.

2026. júl. 2. 23:51 UTC

Mexico's Inflation Rate Release on July 9, 2026: Market Eyes Rising Trends Amid Tariff and Oil Price Concerns.

2026. júl. 2. 23:51 UTC

Mexican Inflation Rate Expected to Decline Further Ahead of July 9 Release, Influencing Market Sentiment Amid Global Trends.

2026. júl. 2. 23:51 UTC

Social Media

Fox Corp shares are lower in after-market hours despite record viewership for the U.S. Men's National Team match, averaging 24.43 million viewers.

2026. júl. 2. 23:51 UTC

Fiserv Inc. shares are higher in after-market trading, reflecting positive sentiment following weaker-than-expected job growth data that has eased rate hike concerns.

2026. júl. 2. 23:51 UTC

Macro News
Social Media
ETF Constituents
Correlated Moves

The KOSPI index fell sharply, impacting the iShares MSCI South Korea ETF, which remained near unchanged in after-hours trading.

2026. júl. 2. 23:51 UTC

Lam Research Corp shares are higher in after-market trading, reflecting positive sentiment following a weaker-than-expected jobs report and tempered rate hike fears.

2026. júl. 2. 23:51 UTC

Terra is trading higher today, continuing its upward momentum since Wednesday's close. The asset remains below its 20-day moving average.

2026. júl. 2. 23:51 UTC

PepsiCo Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid generally positive broader market sentiment.

2026. júl. 2. 23:46 UTC

Correlated Moves

J B Hunt Transport Services Inc shares are higher in after-market trading, following a modest increase since Thursday's close amid stable market conditions.

2026. júl. 2. 23:46 UTC

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting a decline since Thursday's close and nearing its one-month low.

2026. júl. 2. 23:46 UTC

Macro News
ETF Constituents
Correlated Moves

Energy Select Sector SPDR Fund declines after-market, influenced by weak U.S. employment data and slight losses among major holdings like Exxon Mobil and Chevron.

2026. júl. 2. 23:42 UTC

U.S. Trade Deficit Expected to Widen to $78.8 Billion in May 2026 Amid Economic Uncertainties and Geopolitical Tensions

2026. júl. 2. 23:42 UTC

U.S. Exports Data Release on July 7 Expected to Reflect Mixed Performance Amid Global Economic Challenges and Tariff Changes

2026. júl. 2. 23:42 UTC

U.S. Imports Data Release on July 7, 2026, Expected to Reflect Strong Growth Amid Tariff Changes and Supply Chain Adjustments

2026. júl. 2. 23:42 UTC

Canada's Trade Surplus Expected to Continue Amid Geopolitical Tensions Ahead of July 7 Data Release

2026. júl. 2. 23:41 UTC

Correlated Moves

NXP Semiconductors NV shares are higher in after-market trading, reflecting a modest increase since Thursday's close amid gains in Skyworks Solutions Inc.

2026. júl. 2. 23:41 UTC

NetApp Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

2026. júl. 2. 23:41 UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026. júl. 2. 23:41 UTC

Macro News
Correlated Moves

Bitcoin reached a one-week high today, boosted by weaker U.S. employment data and optimism about Federal Reserve rate hikes. Related stocks also gained.

2026. júl. 2. 23:36 UTC

The US Dollar Index is trading roughly flat amid routine price action. European equity markets closed positively, driven by gains in defensive sectors and pharmaceuticals.

2026. júl. 2. 23:36 UTC

Correlated Moves
Macro News
ETF Constituents

The SPDR S&P Bank ETF is higher after hours, supported by Third Coast Bancshares' $30 million share repurchase program and mixed market performance.

2026. júl. 2. 23:36 UTC

Kraft Heinz Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock briefly reached a session high earlier.

2026. júl. 2. 23:32 UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

56.95% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 7 USD  56.95%

Magas 10 USD

Alacsony 4 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

7 ratings

4

Vétel

3

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat